The Highest Percentage of Surveyed PCPs and MCOs Perceive Orlistat (Roche’s Xenical, GlaxoSmithKline’s OTC Alli) to Be the

Surveyed PCPs Who Selected Amylin/Eli Lilly’s Byetta or Novo Nordisk’s Victoza as Having the Best Efficacy Were Most Satisfied With the Effect of These Agents on Diabetes-Related Risk Factors, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highest percentage (32 percent) of surveyed primary care physicians (PCPs) and managed care organization’s (MCOs) pharmacy directors (33 percent) perceive orlistat (Roche’s Xenical, GlaxoSmithKline’s OTC Alli) to be the most efficacious obesity therapy. However, although a greater number of respondents chose orlistat as the most efficacious agent, those who chose it indicate they are only moderately satisfied across all efficacy end points for this agent.

Decision Resources’ analysis of the obesity drug market reveal that although the greatest percentage of surveyed PCPs identified orlistat as the most efficacious therapy as well as having the best overall clinical profile, PCPs are only moderately satisfied with its accessibility. Surveyed PCPs are least satisfied with orlistat’s out-of-pocket costs, while surveyed payers indicate they are dissatisfied with its net price to plan and potential to reduce the cost of the disease.

Surveyed PCPs who selected Amylin/Eli Lilly’s Byetta (exenatide) or Novo Nordisk’s Victoza (liraglutide) as the most efficacious anti-obesity drug were most satisfied with the effect of these two agents on diabetes-related risk factors. Both exenatide and liraglutide are GLP-1 analogues that are approved to treat type 2 diabetes and are used off-label for obesity. Twenty-three percent of surveyed PCPs considered exenatide the most-efficacious obesity therapy, while 13 percent perceived liraglutide as the most efficacious. The fact that fewer PCPs perceived liraglutide as more efficacious than exenatide contradicts the views of interviewed thought leaders, who consider liraglutide to have greater weight-loss efficacy. However, PCPs’ perception may be due to their greater experience with exenatide, which launched in 2005.

The findings also reveal that a greater percentage of surveyed MCOs than PCPs selected phentermine (UCB’s Ionamin, generics) as the most efficacious anti-obesity therapy. Phentermine is approved only for short-term use, a restriction that may explain why fewer surveyed PCPs chose it over orlistat as the most efficacious.

“However, even though only 18 percent of surveyed PCPs selected phentermine as the most efficacious, both surveyed physicians and payers who chose it indicated the highest level of satisfaction with its weight-loss efficacy of any of the agents including in the survey,” said Decision Resources Analyst Kate Sullivan.

The findings also reveal that the obesity drug market will increase more than nine-fold over the next decade, from $477 million in 2009 to more than $4.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Novel emerging agents will experience rapid uptake, owing to the high prevalence of obesity and the lack of efficacious, safe and well-tolerated obesity drugs. The launch of phentermine/topiramate SR (Vivus’s Qnexa) and bupropion SR/naltrexone SR (Orexigen Therapeutics/Takeda’s Contrave) in 2011 will help to fulfill the need for a wider variety of obesity drug options. However, of these two agents, only Qnexa can induce the greater than 10 percent placebo-adjusted weight loss that physicians and patients desire.

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Fitness & Nutrition  Pharmaceutical  Diabetes  General Health

MEDIA:

Logo
 Logo

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.